- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03598374
Spontaneous Reproductive Outcomes After Oral Inositol Supplementation in Infertile Polycystic Ovarian Syndrome Women. (IROP-1)
Effects of Oral Inositol Supplementation on Spontaneous Reproductive Outcomes in Infertile Polycystic Ovarian Syndrome Women.
Polycystic ovarian syndrome (PCOS) is a heterogeneous, multifaceted and complex disorder characterized by insulin resistance (IR), hyperinsulinemia, and hyperandrogenism leading ovarian disfunction and infertility. Given the central pathogenic role of IR in the endocrine, reproductive, and metabolic disturbances of PCOS, several pharmacological and non-pharmacological approaches have been proposed to counteract the hyper insulinemic IR typical of the syndrome. Two Inositol stereoisomers, Myo-Inositol (MI) and D-chiro-inositol (DCI), captured the attention of researchers for their insulin-sensitizing actions, which configure them as proper candidates for the treatment of PCOS.
Very few studies reported on spontaneous clinical pregnancy rates, none were powered for this outcome, and none reported on the clinically relevant outcome of live birth. Therefore, data about clinical pregnancy rate, live birth rate, and miscarriage rate comparing inositols with placebo are limited.
Conversely, about infertility and assisted reproduction techniques (ART), improvements have been reported in PCOS women who underwent fertility treatment using inositol in different forms, combinations or doses. This data, considering the different tissue-specific ratios (i.e., 100:1 in the ovary) and the different physiological roles of inositol stereoisomers, suggest that DCI supplementation alone might not be the optimal or appropriate approach for improving IVF outcomes in PCOS patients, and drawn attention to the importance of MI and DCI supplementation in a physiological ratio in order to restore normal ovary functionality. Indeed, the combination of MI and DCI, at a more physiological ratio of 40:1, was able to more quickly restore to normal the hormonal and metabolic parameters in PCOS women than MI treatment alone or DCI treatment alone, improving the endocrine profile and IR of women with PCOS.
Nevertheless, regarding infertility the primary outcomes that should be considered are clinical pregnancy rate, miscarriage rate and live birth rate. Although many studies showed improved hormonal and metabolic profile and improved ovulation rate and higher quality and number of oocyte retrieved in ART in PCOS women after inositols administration, data about clinical pregnancy rate, live birth rate, and miscarriage rate are limited with several concerns regarding interpretation of the studies.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Women with PCOS diagnosed by Rotterdam criteria in couple that desire to conceive.
Exclusion Criteria:
- Male infertility factor that require in vitro fertilization technique.
- Women with infertility factors that require in vitro fertilization technique.
- Couple with infertility factors that require in vitro fertilization technique.
- Diabetes mellitus that require insulin or oral drugs treatment.
- Any other pre-pregnancy or pregnancy-induced/related disease.
- Any other pharmacological, non-pharmacological or nutraceutical treatment (beside oral folic acid supplementation) more than 3 months before the enrollment (wash-out period) or during the trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Inositol + Folic acid
Couples with PCOS infertile women, diagnosed according to the Rotterdam criteria, who access infertility center with conception desire. These women will receive oral supplementation with Inositol (Myo-inositol and D-chiro-inositol at 40:1 ratio) plus Folic acid for 6 months. Couples are required to have regular intercourse with the aim to achieve a spontaneous conception. |
Daily oral supplementation of for 6 months or until pregnancy conception: Myo-Inositol: 1100 mg D-chiro-inositol: 27.6 mg Folic acid: 400 mcg
Couples are required to have regular intercourses with the aim to achieve a spontaneous conception.
|
PLACEBO_COMPARATOR: Folic acid
Couples with PCOS infertile women, diagnosed according to the Rotterdam criteria, who access infertility center with conception desire. These women will receive oral supplementation with Folic acid for 6 months. Couples are required to have regular intercourse with the aim to achieve a spontaneous conception. |
Couples are required to have regular intercourses with the aim to achieve a spontaneous conception.
Daily oral supplementation of for 6 months: Folic acid: 400 mcg |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical pregnancy rate
Time Frame: Within 6 months from the enrollment
|
Number of spontaneous pregnancies conceived per women diagnosed by transvaginal ultrasound.
Diagnosis is based on the identification of intrauterine gestational sac with embryo and/or yolk sac.
|
Within 6 months from the enrollment
|
Miscarriage rate
Time Frame: Within 6 months from the enrollment
|
Number of spontaneous abortion per women diagnosed by positive pregnancy test with subsequent spontaneous interruption of the pregnancy.
|
Within 6 months from the enrollment
|
Live birth rate
Time Frame: Within 18 months from the enrollment
|
Number of spontaneous pregnancies per women resulted in a delivered viable fetus.
|
Within 18 months from the enrollment
|
Spontaneous ovulation rate
Time Frame: Change in spontaneous ovulation rate, through study completion (an average of 18 months)
|
Spontaneous ovulation activity evaluated by menstrual cycle regularization.
Menstrual cycles evaluated by intervals between menstruations (days), day of menstrual blood flow.
Rate evaluate considering the number of women with restored regular menstrual cycles per women with irregular menstrual cycles.
|
Change in spontaneous ovulation rate, through study completion (an average of 18 months)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Glucose metabolism
Time Frame: Change in glucose metabolism, through study completion (an average of 18 months)
|
OGTT: values of oral glucose tolerance test.
Impaired glucose metabolism is diagnosed if fasting glucose values were abnormal (100-125 mg/dl) or glucose tolerance is impaired (2 h plasma glucose within OGTT range of 140-199 mg/dl), and when glucose values exceed threshold values for gestational diabetes (fasting glu- cose value ≥92mg/dl, 1-hour glucose value ≥180mg/dl or 2- hour glucose value ≥153mg/dl)
|
Change in glucose metabolism, through study completion (an average of 18 months)
|
BMI
Time Frame: Change in BMI, through study completion (an average of 18 months)
|
Body mass index
|
Change in BMI, through study completion (an average of 18 months)
|
Lipid metabolism
Time Frame: Change in Lipid metabolism, through study completion (an average of 18 months)
|
Lipid profile assessed by evaluation the high density lipoprotein level and triglycerides level.
|
Change in Lipid metabolism, through study completion (an average of 18 months)
|
Blood pressure
Time Frame: Change in Blood pressure, through study completion (an average of 18 months)
|
systolic and diastolic blood pressure
|
Change in Blood pressure, through study completion (an average of 18 months)
|
Androgens profile
Time Frame: Change in Androgens profile, through study completion (an average of 18 months)
|
Serum free testosterone, dehydroepiandrosterone sulfate, and serum SHBG serum concentrations.
|
Change in Androgens profile, through study completion (an average of 18 months)
|
Collaborators and Investigators
Collaborators
Investigators
- Study Chair: Massimo Franchi, M.D., Universita di Verona
Study record dates
Study Major Dates
Study Start (ANTICIPATED)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms
- Endocrine System Diseases
- Disease
- Ovarian Cysts
- Cysts
- Ovarian Diseases
- Adnexal Diseases
- Gonadal Disorders
- Polycystic Ovary Syndrome
- Syndrome
- Infertility
- Infertility, Female
- Physiological Effects of Drugs
- Micronutrients
- Vitamins
- Hematinics
- Folic Acid
- Vitamin B Complex
- Inositol
Other Study ID Numbers
- IROP-1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Polycystic Ovarian Syndrome
-
Northwell HealthWithdrawnPolycystic Ovarian Syndrome (PCOS) | Patients Sensitive to Exogenous Gonadotropins | Ovarian Hyper Stimulation Syndrome (OHSS)United States
-
Etlik Zubeyde Hanim Womens' Health and Teaching...CompletedOvarian Hyperstimulation Syndrome | Polycystic Ovarian Syndrome
-
BioromaUnknownOvarian Hyperstimulation Syndrome | Polycystic Ovarian Syndrome | Invitro FertilizationItaly
-
Bruce LesseyTerminatedPolycystic Ovarian SyndromeUnited States
-
Kufa UniversityCompletedPolycystic Ovary SyndromeIraq
-
Duke UniversityTerminatedPolycystic Ovarian SyndromeUnited States
-
V.K.V. American Hospital, IstanbulUnknownPolycystic Ovarian SyndromeTurkey
-
Yunyang Medical CollegeUnknown
-
Mayo ClinicCompletedOverweight | Insulin Resistance | Obese | Polycystic Ovarian Syndrome (PCOS)United States
-
Khyber Medical University PeshawarCompletedPolycystic Ovarian SyndromePakistan
Clinical Trials on Inositol + Folic acid
-
Lo.Li.Pharma s.r.lCompleted
-
Università degli Studi dell'InsubriaUniversita di VeronaNot yet recruitingPolycystic Ovary Syndrome
-
Lo.Li.Pharma s.r.lCompleted
-
Università degli Studi 'G. d'Annunzio' Chieti e...Unknown
-
AGUNCO Obstetrics and Gynecology CentreCompleted
-
AGUNCO Obstetrics and Gynecology CentreUnknownGestational DiabetesItaly
-
Institute of Child HealthCompletedRecurrent Neural Tube DefectsUnited Kingdom
-
AGUNCO Obstetrics and Gynecology CentreCompletedSperm Quality | OligoasthenospermiaItaly
-
AGUNCO Obstetrics and Gynecology CentreCompleted
-
Catholic University of the Sacred HeartCompletedPolycystic Ovary Syndrome | Menstrual Irregularity | HirsutismItaly